Amoxycillin

ApprovedSmall molecule

MMenzies School of Health Research

Amoxycillin is one of 47 small molecule programs targeting Pneumonia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

Otitis MediaActive, not recruiting

PneumoniaPhase 3

Active, not recruiting

Otitis MediaApproved

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Amoxycillin

MMenzies School of Health Research

Approved

1 2

Primaxin

Pfizer

Preclinical

2 3

Prevacid

Takeda

Preclinical

1 4

Innohep

Alnylam Pharmaceuticals

Preclinical

1 5

Acanya

Pfizer

Preclinical

1 6

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

12 7

Zantac 150

CChattem

Preclinical

2 8

Pepcid

KKenvue Brands

Preclinical

1 9

Mucinex

AAultman Health Foundation

Preclinical

1 10

Ofev

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pneumonia1 trial

Indiaclen Short Course Amoxycillin Therapy for Pneumonia With Wheeze

Completed·KKing George's Medical University·Phase 3·NCT00407394·2,000 enrolled

Otitis media1 trial

Long-term Antibiotics for Treatment and Prevention of Otitis Media in Aborignal Children

Completed·MMenzies School of Health Research·Phase 4·NCT00539149·126 enrolled

Age1 trial

Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTs

Completed·—·N/A·NCT00720811·6,456 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Amoxycillin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amoxycillin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amoxycillin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Menzies School of Health Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMenzies School of Health Research

Amoxycillin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pneumonia1 trial

Otitis media1 trial

Age1 trial

References

Drug Info

Quick Facts

Related News